Drugs + Prices -- United States
Label
Drugs + Prices -- United States
Name
Drugs + Prices
Focus
Sub focus
Actions
Incoming Resources
- States' collection of offset and supplemental Medicaid rebates
- Medicare hospital pharmaceuticals, survey shows price variation and highlights data collection lessons and outpatient rate-setting challenges for CMS : report to congressional committees
- FDA and drug prices, facilitating access to generic drugs, Agata Dabrowska
- Constitutional challenges to the medicare drug price negotiation program, Hannah-Alise Rogers
- A prescription for savings, reducing drug costs to Medicare : hearing before the Special Committee on Aging, United States Senate, One Hundred Twelfth Congress, first session, Washington, DC, July 21, 2011
- Limitations in manufacturer reporting of average sales price data for Part B drugs
- Closing the coverage gap, Medicare prescription drugs are becoming more affordable
- Medicare Part B drugs, program payments should reflect market prices, statement of William J. Scanlon, Director, Health Care Issues
- Drug price disclosures and the first amendment, Valerie C. Brannon
- Drug prices, the role of patents and regulatory exclusivities, Erin H. Ward, Kevin J. Hickey, Kevin T. Richards
- Assessment of sponsors' materials under the temporary Medicare-approved drug discount card program
- Strategies used by adults aged 18-64 to reduce their prescription drug costs, 2017, Robin A. Cohen, Peter Boersma, and Anjel Vahratian
- Prescription drugs, prices available through discount cards and from other sources
- Purple Book Continuity Act of 2019, report (to accompany H.R. 1520) (including cost estimate of the Congressional Budget Office)
- Medicare Part D, prescription drug benefit, increasing use and access of affordable prescription drugs : a report of the Special Committee on Aging, United States Senate
- Medicare, payments for covered outpatient drugs exceed providers' cost
- Coverage and pricing of drugs that can be covered under Part B and Part D, final report, Elizabeth Hargrave, Jack Hoadley and Jennifer Thompson ; submitted to the Medicare Payment Advisory Commission
- Are Medicare allowances for Albuterol Sulfate reasonable?
- Update, excessive Medicare reimbursement for ipratropium bromide
- Drug manufacturers' noncompliance with average manufacturer price reporting requirements
- Description of subtitle J - drug pricing, budget reconciliation legislative recommendations : scheduled for markup by the House Committee on Ways and Means on September 14, 2021, prepared by the staff of the Joint Committee on Taxation
- Medicare drug reimbursements, a broken system for patients and taxpayers : joint hearing before the Subcommittee on Health and the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, September 21, 2001
- A comparison of albuterol sulfate prices
- Prices for brand-name drugs under selected federal programs
- Medicare, comments on CMS proposed 2006 rates for specified covered outpatient drugs and radiopharmaceuticals used in hospitals
- Administrative Procedure Act challenges to CMS's implementation of the Medicare Drug Price Negotiation Program, Hannah-Alise Rogers
- Pay to delay, are patent settlements that delay generic drug market entry anticompetitive? : hearing before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, House of Representatives, One Hundred Eleventh Congress, first session, June 3, 2009
- Deficiencies in the oversight of the 340B drug pricing program
- Short supply, the health and national security risks of drug shortages : HSGAC majority staff report
- Special report of the U.S. Senate Special Committee on Aging on the sudden price spikes in off-patent prescription drugs, the monopoly business model that harms patients, taxpayers, and the U.S. health system
- Excessive Medicare payments for prescription drugs
- Replacing average wholesale price, Medicaid drug payment policy
- Excessive Medicare reimbursement for Albuterol
- Outpatient prescription medicines, a comparison of expenditures by household-reported condition, 1987 and 2001, Marie N. Stagnitti and Mamatha Pancholi
- Drug shortages, causes, FDA authority, and policy options, Agata Dabrowska
- Fin de la interrupciĆ³n de la cobertura
- Drug pricing and intellectual property, the legislative landscape for the 117th Congress, Kevin J. Hickey, Kevin T. Richards, Erin H. Ward
- Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending, testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives, statement by John E. Dicken
- Medicare, drug purchase prices for CMS consideration in hospital outpatient rate-setting
- Drug prices paid by DOD and VA are, on average, lower than those certified to HCFA as best price, United States General Accounting Office
- Medicare reimbursement of albuterol
- The truth about the drug companies, how they deceive us and what to do about it, Marcia Angell
- Outpatient prescribed medicines, a comparison of use and expenditures, 1987 and 2001, Mamatha Pancholi and Marie Stagnitti
- Pharmaceutical prices and draft legislation on homeless veterans' programs and issues related to Persian Gulf War illness, hearing before the Subcommittee on Health of the Committee on Veterans' Affairs, House of Representatives, One Hundred Fifth Congress, first session, July 10, 1997
- DOD and VA pharmacy, progress and remaining challenges in jointly buying and mailing out drugs : report to Congressional requesters, United States General Accounting Office
- Prescription drugs, out-of-pocket expenses and unmet need relative to family income, 2002, Beth Levin Crimmel and Marie N. Stagnitti
- Prescription drug issues in the Department of Veterans Affairs, hearing before the Committee on Veterans' Affairs, United States Senate, One Hundred Seventh Congress, first session, July 24, 2001
- Safeguarding pharmaceutical supply chains in a global economy, hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, October 30, 2019
- Prescription drug shortages, examining a public health concern and potential solutions : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth Congress, first session ... December 15, 2011
- Update, excessive Medicare reimbursement for albuterol
Outgoing Resources
- Focus1
- Sub focus3